Others have been recently approved for the treatment of specific breast cancer subtypes, such as the mTOR inhibitor everolimus in advanced luminal breast cancer and the poly(ADP-ribose)polymerase (PARP) inhibitor olaparib in metastatic breast cancer with germline BRCA1 or BRCA2 mutations [6–9]. Here, BRCA1 is linked to breast cancer.